Last update 21 Nov 2024
SENL101
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms CD7-Specific CAR-T Cells(Hebei Senlangbio), KO7CAR, SENL101自体T细胞（河北森朗） + [4] |
Target |
Mechanism CD7 inhibitors(T-cell antigen CD7 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Login to view timeline
Related
8
Clinical Trials associated with SENL101SENL101自体T细胞注射液治疗成人复发或难治性T淋巴母细胞淋巴瘤/白血病（T-LBL/ALL）患者的开放标签、剂量递增的I期临床研究
[Translation] An open-label, dose-escalating phase I clinical study of SENL101 autologous T cell injection in the treatment of adult patients with relapsed or refractory T-lymphoblastic lymphoma/leukemia (T-LBL/ALL)
Open-label, Dose-escalation Phase 1 Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory T-LBL/ALL
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T Lymphoblastic Leukemia and T Lymphoblastic Lymphoma
100 Clinical Results associated with SENL101
Login to view more data
100 Translational Medicine associated with SENL101
Login to view more data
100 Patents (Medical) associated with SENL101
Login to view more data
100 Deals associated with SENL101
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Hodgkin Lymphoma | Phase 1 | CN | 12 Oct 2022 | |
| T-Cell Lymphoma | Phase 1 | CN | 01 May 2022 | |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | CN | 01 Oct 2020 | |
| T-cell Acute Lymphoblastic Leukemia/Lymphoma | IND Application | CN | 04 Apr 2023 | |
| Adult Lymphoblastic Lymphoma | Preclinical | US | 31 Aug 2023 | |
| Acute Lymphoblastic Leukemia | Preclinical | CN | 01 Oct 2020 | |
| CD7 Positive T-Cell Leukemia | Preclinical | CN | 01 Oct 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 53 | (llfeppcryp) = kwmtrnowlm cxovjarlul (krjcchtiqn ) View more | Positive | 15 Nov 2022 | |||
Phase 1 | 15 | KO7CAR T-cells+Fludarabine Phosphate+Cyclophosphamide | (rmuvmojpra) = wsqrnirgcg wybwhejhvt (sachtuntlb ) View more | Positive | 12 May 2022 | ||
Phase 1 | 20 | (qhezabacbs) = 2pts neurotoxicity jjtnvqkekw (cadmvwefhg ) View more | Positive | 02 May 2022 | |||
NCT04938115 (ASH2021) Manual  | Phase 1 | Mixed phenotype acute leukemia CD7 Positive | 5 | coltsctdif(qzmnttzciq) = qrtulgqdum qkkfupilpb (wyuwhsqcgu ) View more | Positive | 05 Nov 2021 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free